COXANTO Drug Patent Profile
✉ Email this page to a colleague
When do Coxanto patents expire, and when can generic versions of Coxanto launch?
Coxanto is a drug marketed by Solubiomix and is included in one NDA.
The generic ingredient in COXANTO is oxaprozin. There are thirteen drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the oxaprozin profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Coxanto
A generic version of COXANTO was approved as oxaprozin by ABRAXEOLUS on January 31st, 2001.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for COXANTO?
- What are the global sales for COXANTO?
- What is Average Wholesale Price for COXANTO?
Summary for COXANTO
US Patents: | 0 |
Applicants: | 1 |
NDAs: | 1 |
Finished Product Suppliers / Packagers: | 2 |
What excipients (inactive ingredients) are in COXANTO? | COXANTO excipients list |
DailyMed Link: | COXANTO at DailyMed |
Pharmacology for COXANTO
Drug Class | Nonsteroidal Anti-inflammatory Drug |
Mechanism of Action | Cyclooxygenase Inhibitors |
US Patents and Regulatory Information for COXANTO
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Solubiomix | COXANTO | oxaprozin | CAPSULE;ORAL | 217927-001 | Oct 20, 2023 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |